Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 29Terminated 5Not yet recruiting 3Active not recruiting 3Recruiting 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 14Neoplasm Metastasis 7Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Stomach Neoplasms 2Ovarian Neoplasms 2Metastatic Pancreatic Ductal Adenocarcinoma 2Lung Neoplasms 2Inflammatory Breast Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Unresectable Biliary Tract Cancer 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thromboembolism 1TNBC 1Sarcoma 1Peritoneal Neoplasms 1Oropharyngeal Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Mouth Neoplasms 1Locally Advanced or Metastatic Solid Tumours 1Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy 1Lip Neoplasms 1Laryngeal Neoplasms 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 25Cyclophosphamide 20Nivolumab 13Doxorubicin 13Carboplatin 10Surveys and Questionnaires 9Paclitaxel 9Exercise 9atezolizumab 8Vincristine 8Rituximab 8Radiotherapy 8Prednisone 8Dexamethasone 8Bevacizumab 8venetoclax 7fludarabine 7Pemetrexed 7Fluorouracil 7Docetaxel 7Blood Specimen Collection 7lenvatinib 6dostarlimab 6cemiplimab 6budigalimab 6Oxaliplatin 6Cisplatin 6durvalumab 5Leucovorin 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT06360354 2026-06-01

MTAPESTRY 103

Amgen

Phase 1 Active not recruiting
120 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03530397 2026-05-19

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

MedImmune LLC

Phase 1 Active not recruiting
400 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT03893955 2025-08-12

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

AbbVie

Phase 1 Active not recruiting
150 enrolled
BreastThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡